Abstract Objective: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of chronic liver disease worldwide and is largely driven by chronic inflammation and hepatic immune dysregulation. The receptor activator of nuclear factor-κB ligand (RANKL) is a master regulator of bone metabolism with emerging immunomodulatory functions. Although growing evidence links the RANK-RANKL-OPG axis to MASH pathophysiology, whether RANKL blockade attenuates MASH development remains unclear.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile